Cargando…
Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment
Ischemia and reperfusion injury (IRI) is a common complication caused by inflammation and oxidative stress resulting from liver surgery. Current therapeutic strategies do not present the desirable efficacy, and severe side effects can occur. To overcome these drawbacks, new therapeutic alternatives...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779145/ https://www.ncbi.nlm.nih.gov/pubmed/35057000 http://dx.doi.org/10.3390/pharmaceutics14010104 |
_version_ | 1784637499639857152 |
---|---|
author | Ferreira-Silva, Margarida Faria-Silva, Catarina Carvalheiro, Manuela C. Simões, Sandra Marinho, H. Susana Marcelino, Paulo Campos, Maria Celeste Metselaar, Josbert M. Fernandes, Eduarda Baptista, Pedro V. Fernandes, Alexandra R. Corvo, Maria Luísa |
author_facet | Ferreira-Silva, Margarida Faria-Silva, Catarina Carvalheiro, Manuela C. Simões, Sandra Marinho, H. Susana Marcelino, Paulo Campos, Maria Celeste Metselaar, Josbert M. Fernandes, Eduarda Baptista, Pedro V. Fernandes, Alexandra R. Corvo, Maria Luísa |
author_sort | Ferreira-Silva, Margarida |
collection | PubMed |
description | Ischemia and reperfusion injury (IRI) is a common complication caused by inflammation and oxidative stress resulting from liver surgery. Current therapeutic strategies do not present the desirable efficacy, and severe side effects can occur. To overcome these drawbacks, new therapeutic alternatives are necessary. Drug delivery nanosystems have been explored due to their capacity to improve the therapeutic index of conventional drugs. Within nanocarriers, liposomes are one of the most successful, with several formulations currently in the market. As improved therapeutic outcomes have been demonstrated by using liposomes as drug carriers, this nanosystem was used to deliver quercetin, a flavonoid with anti-inflammatory and antioxidant properties, in hepatic IRI treatment. In the present work, a stable quercetin liposomal formulation was developed and characterized. Additionally, an in vitro model of ischemia and reperfusion was developed with a hypoxia chamber, where the anti-inflammatory potential of liposomal quercetin was evaluated, revealing the downregulation of pro-inflammatory markers. The anti-inflammatory effect of quercetin liposomes was also assessed in vivo in a rat model of hepatic IRI, in which a decrease in inflammation markers and enhanced recovery were observed. These results demonstrate that quercetin liposomes may provide a significant tool for addressing the current bottlenecks in hepatic IRI treatment. |
format | Online Article Text |
id | pubmed-8779145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87791452022-01-22 Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment Ferreira-Silva, Margarida Faria-Silva, Catarina Carvalheiro, Manuela C. Simões, Sandra Marinho, H. Susana Marcelino, Paulo Campos, Maria Celeste Metselaar, Josbert M. Fernandes, Eduarda Baptista, Pedro V. Fernandes, Alexandra R. Corvo, Maria Luísa Pharmaceutics Article Ischemia and reperfusion injury (IRI) is a common complication caused by inflammation and oxidative stress resulting from liver surgery. Current therapeutic strategies do not present the desirable efficacy, and severe side effects can occur. To overcome these drawbacks, new therapeutic alternatives are necessary. Drug delivery nanosystems have been explored due to their capacity to improve the therapeutic index of conventional drugs. Within nanocarriers, liposomes are one of the most successful, with several formulations currently in the market. As improved therapeutic outcomes have been demonstrated by using liposomes as drug carriers, this nanosystem was used to deliver quercetin, a flavonoid with anti-inflammatory and antioxidant properties, in hepatic IRI treatment. In the present work, a stable quercetin liposomal formulation was developed and characterized. Additionally, an in vitro model of ischemia and reperfusion was developed with a hypoxia chamber, where the anti-inflammatory potential of liposomal quercetin was evaluated, revealing the downregulation of pro-inflammatory markers. The anti-inflammatory effect of quercetin liposomes was also assessed in vivo in a rat model of hepatic IRI, in which a decrease in inflammation markers and enhanced recovery were observed. These results demonstrate that quercetin liposomes may provide a significant tool for addressing the current bottlenecks in hepatic IRI treatment. MDPI 2022-01-03 /pmc/articles/PMC8779145/ /pubmed/35057000 http://dx.doi.org/10.3390/pharmaceutics14010104 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ferreira-Silva, Margarida Faria-Silva, Catarina Carvalheiro, Manuela C. Simões, Sandra Marinho, H. Susana Marcelino, Paulo Campos, Maria Celeste Metselaar, Josbert M. Fernandes, Eduarda Baptista, Pedro V. Fernandes, Alexandra R. Corvo, Maria Luísa Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment |
title | Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment |
title_full | Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment |
title_fullStr | Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment |
title_full_unstemmed | Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment |
title_short | Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment |
title_sort | quercetin liposomal nanoformulation for ischemia and reperfusion injury treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779145/ https://www.ncbi.nlm.nih.gov/pubmed/35057000 http://dx.doi.org/10.3390/pharmaceutics14010104 |
work_keys_str_mv | AT ferreirasilvamargarida quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT fariasilvacatarina quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT carvalheiromanuelac quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT simoessandra quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT marinhohsusana quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT marcelinopaulo quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT camposmariaceleste quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT metselaarjosbertm quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT fernandeseduarda quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT baptistapedrov quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT fernandesalexandrar quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment AT corvomarialuisa quercetinliposomalnanoformulationforischemiaandreperfusioninjurytreatment |